Menarini buys rights to AML candidate from Helsinn Group

21 December 2018

Swiss oncology specialist Helsinn has granted a German subsidiary of Menarini exclusive global licencing rights for pracinostat, excluding the USA, Canada, Japan and South America.

Berlin Chemie has picked up the rights to pracinostat, an inhibitor of class I, II, and IV histone deacetylase, currently in Phase III development in combination with azacitidine for acute myeloid leukemia (AML).

The trial is testing the combo in adults who are unfit for intensive induction chemotherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK